|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.85 USD | +0.19% |
|
-0.69% | -2.56% |
| 12-12 | US FDA approves Innoviva's oral antibiotic for gonorrhea | RE |
| 12-12 | Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 | CI |
| Capitalization | 147B 125B 117B 110B 203B 13,312B 221B 1,365B 530B 6,275B 551B 540B 22,894B | P/E ratio 2025 * |
13.4x | P/E ratio 2026 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise value | 188B 160B 149B 140B 259B 16,993B 283B 1,743B 676B 8,010B 704B 689B 29,225B | EV / Sales 2025 * |
3x | EV / Sales 2026 * | 2.99x |
| Free-Float |
59.04% | Yield 2025 * |
6.6% | Yield 2026 * | 6.73% |
Last Transcript: Pfizer Inc.
| 1 day | +0.19% | ||
| 1 week | -0.69% | ||
| Current month | +0.43% | ||
| 1 month | -0.08% | ||
| 3 months | +8.29% | ||
| 6 months | +4.07% | ||
| Current year | -2.56% |
| 1 week | 25.13 |  | 26.19 |
| 1 month | 24.28 | | 26.19 |
| Current year | 20.92 | | 27.69 |
| 1 year | 20.92 | | 27.69 |
| 3 years | 20.92 | | 54.93 |
| 5 years | 20.92 | | 61.71 |
| 10 years | 20.92 | | 61.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 63 | 31/12/2018 |
David Denton
DFI | Director of Finance/CFO | 60 | 01/05/2022 |
| Chief Tech/Sci/R&D Officer | - | 23/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 67 | 31/08/2007 |
Shantanu Narayen
BRD | Director/Board Member | 61 | 26/09/2013 |
Albert Bourla
CHM | Chairman | 63 | 31/12/2019 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 14.74% | 303 M€ | -21.05% | - |
| 9.37% | 26 M€ | +12.27% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.19% | -0.69% | +1.89% | -50.44% | 147B | |
| +1.80% | +1.70% | +31.34% | +179.78% | 920B | |
| +0.75% | +4.78% | +44.68% | +18.97% | 510B | |
| -0.29% | -1.22% | +28.95% | +35.08% | 395B | |
| -0.35% | +1.90% | +23.99% | +4.55% | 340B | |
| -1.12% | -1.09% | +27.21% | +18.45% | 278B | |
| -0.45% | -1.48% | +19.80% | +24.22% | 254B | |
| +1.30% | +0.58% | -0.94% | -7.96% | 249B | |
| +0.45% | +3.73% | -59.06% | -29.63% | 224B | |
| +0.11% | -3.68% | +15.94% | +14.80% | 171B | |
| Average | -0.01% | +0.45% | +13.38% | +20.78% | 348.89B | |
| Weighted average by Cap. | -0.03% | +1.07% | +21.02% | +53.96% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 62.52B 53.26B 49.75B 46.81B 86.18B 5,663B 94.15B 581B 225B 2,669B 235B 230B 9,738B | 61.74B 52.6B 49.13B 46.23B 85.11B 5,592B 92.98B 573B 222B 2,636B 232B 227B 9,617B |
| Net income | 11.1B 9.46B 8.84B 8.31B 15.3B 1,006B 16.72B 103B 40B 474B 41.66B 40.78B 1,729B | 13.05B 11.12B 10.39B 9.77B 17.99B 1,182B 19.65B 121B 47.02B 557B 48.97B 47.94B 2,033B |
| Net Debt | 40.64B 34.62B 32.34B 30.43B 56.02B 3,681B 61.2B 378B 146B 1,735B 152B 149B 6,331B | 37.8B 32.2B 30.08B 28.3B 52.1B 3,423B 56.92B 351B 136B 1,614B 142B 139B 5,887B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 25.85 $ | +0.19% | 51,599,710 |
| 11/12/25 | 25.80 $ | +0.08% | 35,570,246 |
| 10/12/25 | 25.78 $ | +1.78% | 43,635,410 |
| 09/12/25 | 25.33 $ | -1.71% | 43,483,806 |
| 08/12/25 | 25.77 $ | -1.00% | 45,209,347 |
Delayed Quote Nyse, December 12, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PFE Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition